CA2926888C - Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation - Google Patents

Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation Download PDF

Info

Publication number
CA2926888C
CA2926888C CA2926888A CA2926888A CA2926888C CA 2926888 C CA2926888 C CA 2926888C CA 2926888 A CA2926888 A CA 2926888A CA 2926888 A CA2926888 A CA 2926888A CA 2926888 C CA2926888 C CA 2926888C
Authority
CA
Canada
Prior art keywords
sulfated polysaccharide
platelets
glycosaminoglycan
cell
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2926888A
Other languages
English (en)
French (fr)
Other versions
CA2926888A1 (en
Inventor
Hans-Ake Fabricius
Original Assignee
Cell Receptor SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Receptor SA filed Critical Cell Receptor SA
Publication of CA2926888A1 publication Critical patent/CA2926888A1/en
Application granted granted Critical
Publication of CA2926888C publication Critical patent/CA2926888C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2926888A 2013-10-22 2014-10-22 Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation Active CA2926888C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102013111630 2013-10-22
DE102013111630.2 2013-10-22
PCT/EP2014/072620 WO2015059177A1 (en) 2013-10-22 2014-10-22 Sulfated polysaccharides for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
CA2926888A1 CA2926888A1 (en) 2015-04-30
CA2926888C true CA2926888C (en) 2020-03-24

Family

ID=51795625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2926888A Active CA2926888C (en) 2013-10-22 2014-10-22 Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation

Country Status (6)

Country Link
US (1) US10098906B2 (https=)
EP (1) EP3060223B1 (https=)
JP (1) JP6444399B2 (https=)
AU (1) AU2014339000B2 (https=)
CA (1) CA2926888C (https=)
WO (1) WO2015059177A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434085B2 (en) 2015-06-04 2019-10-08 University Of North Carolina At Greensboro Non-aromatic difluoro analogues of resorcylic acid lactones
EP3402812B1 (en) * 2016-01-11 2024-03-27 Dignity Health Modulators of zinc activated cation channel
AU2018319344B2 (en) * 2017-08-23 2024-04-04 Cell Receptor AG Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US20060154894A1 (en) 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
EP2398482B1 (en) * 2009-02-17 2017-04-19 NovelMed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
EP2550004A4 (en) * 2010-03-12 2014-07-02 Univ Australian HEPARANSULFATERSATZTHERAPIE
IT1401253B1 (it) * 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
TWI520740B (zh) * 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
EP2861273B1 (en) * 2012-06-13 2017-08-23 ExThera Medical Corporation Use of heparin and carbohydrates to treat cancer
US20150328254A1 (en) * 2014-04-17 2015-11-19 Memorial Sloan Kettering Cancer Center Fucoidan nanogels and methods of their use and manufacture

Also Published As

Publication number Publication date
EP3060223A1 (en) 2016-08-31
JP2016534078A (ja) 2016-11-04
JP6444399B2 (ja) 2018-12-26
US20160367589A1 (en) 2016-12-22
CA2926888A1 (en) 2015-04-30
US10098906B2 (en) 2018-10-16
EP3060223B1 (en) 2017-08-30
WO2015059177A1 (en) 2015-04-30
AU2014339000A1 (en) 2016-04-28
AU2014339000B2 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
RS57214B1 (sr) Upotreba derivata hemijski modifikovanog heparina za bolest srpastih ćelija
CA2107365A1 (en) New non-anticoagulant heparin derivatives
CA2407065A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
Fan et al. Relationship of the inhibition of cell migration with the structure of ginseng pectic polysaccharides
Liu et al. The effect of different substitute groups and molecular weights of fucoidan on neuroprotective and anticomplement activity
Zhang et al. Mechanistic insights into cellular immunity of chondroitin sulfate A and its zwitterionic N-deacetylated derivatives
CA2926888C (en) Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation
Volpi Condrosulf®: structural characterization, pharmacological activities and mechanism of action
Hou et al. Polysaccharides and their depolymerized fragments from Costaria costata: Molecular weight and sulfation-dependent anticoagulant and FGF/FGFR signal activating activities
Volpi Dermatan sulfate: Recent structural and activity data
CA2598331A1 (en) Amide derivatives of hyaluronic acid in osteoarthrosis
US11559544B2 (en) Combination of a MAPK/ERK pathway inhibitor and a glycosaminoglycan for the treatment of cancer
CA2472093C (en) Use of sulfated glycosaminoglycans for establishing effective labor in women
Oreste et al. Semi-synthetic heparinoids
Franz et al. Pharmacological activities of sulfated carbohydrate polymers
Murali et al. Comparative assessment of the effects of gender-specific heparan sulfates on mesenchymal stem cells
Carrabs Role of microvesicles in gonarthrosis and their modulation by hyaluronic acid administered in viscosupplementation for the rational development of innovative medical devices
Arumugam et al. Biological activities of heparan sulfate
Macie-Hulme Gemst,.. an, Sanderson, P
Tian et al. Purification, Structural Characterization, and Anticoagulant Activity of Chondroitin Sulfate/Dermatan Sulfate from Cobra (Naja naja atra)
Vercruysse Hyaluronan: A simple molecule with complex character
US20170312305A1 (en) Pharmaceutical extracts and uses thereof
Toida Structure and Bioactivity of Acidic Polysaccharides from Natural Resources
Wang et al. Exploring the Relationship between Hyaluronic Acid Size and Biological Activity: A Review

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171121

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - SMALL

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - SMALL

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251013

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251013